Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medication Adherence Budgets Rising At Pharma Firms, Report Says, But Impact Still Hard To Calculate

Executive Summary

Pharmaceutical companies are investing more money into medication adherence programs, but measuring the success of these programs remains a challenge. Consultants are recommending building adherence plans into the development of a drug, with an emphasis on understanding patients’ approaches to compliance.

You may also be interested in...



Most Common Reason For Poor Rx Adherence: “I Forgot” – NCPA

A study conducted for the National Community Pharmacists Association assigns chronic medication users report card grades based on rates of different non-adherent behaviors and describes the most common reasons along with some possible remedies.

Drug Development Needs “Clean-Slate Think” To Involve Patients All Along The Way – Pfizer’s Lewis-Hall

Drug companies and other stakeholders should collaborate on developing a “clear framework” for patient engagement, Freda Lewis-Hall says at ISPOR.

CBO Legislative Scores Will Account For Medicare Rx’s Reductions In Other Medical Costs

In a policy change, the Congressional Budget Office, which estimates the impact of legislation on federal spending, will account for pharmaceuticals’ effect on overall medical spending in Medicare for bills that directly affect drug use.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS055456

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel